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Abstract
Objectives: Steroids are a mainstay of treatment in orthotopic liver transplantation (OLT) and are
associated with significant morbidity. This trial was conducted to assess the efficacy of steroids
avoidance.
Methods: Patients undergoing OLT between June 2002 and April 2005 were entered into a prospective,
randomized trial of complete steroids avoidance and followed until November 2011. Recipients received
either standard therapy (n = 50) or complete steroids avoidance (n = 50). Analyses were performed on an
intention-to-treat basis. The mean follow-up of all recipients was 2095  117 days. Sixteen (32%)
recipients randomized to the steroids avoidance group ultimately received steroids for clinical indications.
Results: Incidences of diabetes and hypertension prior to or after OLT were similar in both groups, as
was the incidence of rejection. Patient and graft survival rates at 1, 3 and 5 years were lower in the
steroids avoidance group than in the standard therapy group (patient survival: 1-year, 80% versus 86%;
3-year, 68% versus 76%; 5-year, 60% versus 72%; graft survival: 1-year, 76% versus 76%; 3-year, 64%
versus 74%; 5-year, 56% versus 72%), but the differences were not statistically different.
Conclusions: Complete steroids avoidance provides liver transplant recipients with minimal benefit and
appears to result in a concerning trend towards decreased graft and recipient survival. The present data
support the use of at least a short course of steroids after liver transplantation.
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Introduction
As a result of their efficacy in the prevention and treatment of
rejection, corticosteroids have been a key factor in the induction
and maintenance of immunosuppression since the early days of
liver transplantation.1 However, the longterm use of steroids is
associated with a multitude of adverse side-effects, such as hyper-
tension, diabetes, infections and hypercholesterolaemia.2 Steroid
use has also been associated with increased severity of recurrent
hepatitis C virus (HCV) infection post-transplant3,4 and steroid
boluses that are administered for acute rejection are associated
with the greatest level of risk.5 Furthermore, although steroids
may reduce the incidence of early rejection post-transplant, the
importance of preventing mild rejection may be lower in liver
recipients than in recipients of other solid organs. By contrast,
mild rejection has been associated with improved longterm graft
and patient survival in liver recipients without HCV infection.5,6
Newer immunosuppressants have allowed steroid use to be
reduced or potentially avoided altogether, causing uncertainty
about the role of steroids in liver transplant recipients.
Multiple studies examining early withdrawal of steroids follow-
ing liver transplantation did not demonstrate a negative impact
on the incidence of rejection, nor on patient and graft survival,
but did show a potential benefit by reducing the incidence of
steroid-related side-effects.7–17 Other studies have also demon-
strated a reduction in the severity of HCV recurrence when the*These authors contributed equally to this paper.
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use of steroids after liver transplant is minimized.18–21 Many small
retrospective and pilot studies have examined complete steroids
avoidance using several different immunosuppression regimens,
and have demonstrated the safety of these regimens without
impact on patient or graft survival, but have shown variable
success in limiting morbidity associated with steroids.6,22–27
The effect of complete steroids avoidance (i.e. no steroids for
the induction or maintenance of immunosuppression) on out-
comes after liver transplantation remains unclear. Therefore, 100
primary adult liver transplant recipients were prospectively rand-
omized to either standard therapy with steroids or standard
therapy with complete steroids avoidance.
Materials and methods
The University of Michigan Institutional Review Board for
Human Subject Research approved this study. Written informed
consent was obtained from patients. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration of
Helsinki.
Study population
All consecutive, consenting candidates undergoing liver trans-
plantation at the University of Michigan between June 2002 and
May 2005 were enrolled into a prospective, open-label, rand-
omized controlled trial (RCT) to evaluate the effects of complete
steroids avoidance. Enrolled candidates were randomized to either
the ‘steroids’ or ‘no-steroids’ groups using a closed-envelope
system. Only candidates for a primary liver allograft were eligible
for the study. Exclusion criteria refused participation to candi-
dates aged <18 years, multiple organ recipients and patients who
required post-transplant steroid therapy for an indication other
than the prevention of rejection, such as autoimmune hepatitis or
inflammatory bowel disease. Patient and graft survival were then
recorded to 2011.
Immunosuppression and treatment of rejection
Patients randomized to the steroids group received a standard
immunosuppression regimen consisting of tacrolimus, mycophe-
nolate mofetil (MMF), and one dose of dexamethasone 50 mg
intraoperatively followed by a 3–6-month taper of prednisone.
Patients randomized to the no-steroids group received the same
standard immunosuppression therapy as did patients in the ster-
oids group except that induction and maintenance steroids were
not administered. Both groups were given the same target levels
for tacrolimus (postoperative days 0–30, 12–15 ng/ml; postopera-
tive days 31–60, 8–12 ng/ml; >60 days postoperatively, 4–8 ng/ml).
Basiliximab, an interleukin-2 receptor inhibitor, was administered
on the day of transplant and on post-transplant day 4 for liver
transplant recipients with acute renal insufficiency or oliguria.
Tacrolimus was withheld for up to 4 days postoperatively in
patients who received basiliximab.
Clinically suspected rejection was evaluated by liver biopsy and,
when confirmed, treated with high-dose methylprednisolone
(250 mg daily for 3 days). A second course of high-dose steroids
was administered to patients who did not respond. Steroid-
resistant rejection was treated with antibody therapy (OKT3 or
polyclonal antithymocyte globulin). There were no protocol
biopsies in this trial.
Data collection
Donor and recipient variables collected prospectively included
recipient demographic data [body mass index (BMI), cholesterol
profiles, use of pre-transplant insulin and anti-hypertensive medi-
cations], donor demographics, and intraoperative variables. In
addition, recipient BMI, cholesterol profiles, use of insulin and
anti-hypertensive medications were evaluated at 6 months and 12
months post-transplant. Those enrolled in the steroids-free arm
undergoing retransplantation received standard steroid-based
induction and maintenance therapy. Graft survival was defined as
the survival of the initial liver transplant until either retransplan-
tation or death. Postoperative complications were assessed,
including acute cellular rejection, chronic ductopenic rejection,
hepatitis C recurrence, infections at 30 days postoperatively,
primary non-function, postoperative bleeding requiring reopera-
tion, hepatic artery thrombosis, biliary leak and/or stricture,
hepatic vein or inferior vena cava stenosis, renal failure requiring
haemodialysis, and retransplantation. Superficial skin infection
was defined as an operative site infection that required opening of
the wound. Pneumonia, bloodstream infections, peritonitis,
urinary tract infections and other infections were counted only
when clinical suspicion was confirmed by culture. Hepatitis C
recurrence was defined as a persistent elevation of liver enzymes to
1.5 times the normal level for 3 months consecutively that was
not explained by any other diagnosis28 and detectable HCV RNA
levels in post-transplant serum, and confirmed by biopsy. Diabe-
tes was defined by the requirement for either oral hypoglycaemic
medications or insulin. Hypertension was defined as the need for
anti-hypertensive medication to control blood pressure.
Primary endpoints for this study were patient and graft sur-
vival, as well as biopsy-proven rejection. Secondary endpoints
were hepatitis C recurrence, and postoperative metabolic, infec-
tious and transplant-specific complications.
Statistical analysis
Outcomes in the two study arms were compared on an intention-
to-treat basis. All univariate comparisons were unpaired, and all
tests of significance were two-tailed. For univariate analyses, con-
tinuous variables were compared by Student’s t-test with equal or
unequal variance as determined by F-test analysis of the variability
of each variable. Categorical data were compared using chi-
squared analysis. Values are expressed as the mean  standard
deviation (for continuous variables) or as a percentage of
the group from which they were derived (for categorical vari-
ables). Patient and graft survival rates were compared using
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Kaplan–Meier analysis curves with log-rank test to determine sig-
nificance. P-values of <0.05 were considered to indicate statistical
significance. StatView Version 5.0.1 (SAS Institute, Inc., Cary, NC,
USA) was used for statistical analysis.
Results
During the period from June 2002 to May 2005, a total of 190
potential subjects were assessed (Fig. 1). Of these, 135 met the
study inclusion criteria, but 35 refused to participate. Overall, 100
consecutive, consenting patients who underwent primary liver
transplantation were enrolled in this study. Each group included
50 patients. Mean follow-up was 2095  117 days. Donor and
recipient characteristics are summarized in Table 1. The two
groups of recipients were well matched with respect to gender, age,
race, cause of liver failure, comorbidities, Model of End-stage
Liver Disease (MELD) score, renal function and ischaemic times.
Sixteen of 50 recipients (32%) in the steroids-avoidance group
required steroids for biopsy-proven rejection (n = 10), adrenal
insufficiency (n = 1), treatment of sepsis (n = 1), calcineurin
inhibitor toxicity (n = 1), autoimmune thrombocytopenia (n = 1),
physician decision (n = 1) or suspected post-transplant autoim-
mune hepatitis (n = 1). The two study groups were also similar in
donor characteristics with respect to gender, age, race, cause of
death, and cytomegalovirus (CMV) positivity.
Postoperative complications were compared between the two
groups (Table 2). There was no difference in the incidence of
rejection or the time to the first episode of acute rejection. All
rejection episodes responded to pulsed high-dose steroid therapy.
No differences were seen in occurrences of primary non-function,
hepatic artery thrombosis, hepatic vein/inferior vena cava steno-
sis, biliary complications (leak and/or stricture), renal failure or
Patients screened 
n = 190 
Eligible subjects 
n = 135 
Excluded 
n = 35 (refused to participate) 
Randomized 
n = 100 
Steroids 
n = 50 
No steroids 
n = 50 
Treated with steroids post-transplant 
n = 16 
Indication: 
Biopsy proven rejection n = 10 
Adrenal insufficiency n = 1 
Treatment of sepsis n = 1 
Calcineurin inhibitor toxicity n = 1 
Autoimmune thrombocytopenia n = 1 
Physician decision n = 1 
Suspected posttransplant autoimmune hepatitis n = 1 
Excluded 
n = 55 
(51 did not meet criteria, 4 not 
approached because staff   
were unavailable for consent)
Figure 1 Flow diagram illustrating study enrolment and disposition of participants
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re-exploration for bleeding. There was a statistically significant
increase in retransplantation in the no-steroids group, in which
six patients underwent a second transplant and two of these
required a third transplant, whereas no patients in the steroids
group were retransplanted. The reasons for retransplantation
included: primary non-function (n = 2); hepatic artery
thrombosis (n = 2); early rejection (n = 1) which was successfully
treated, but the patient subsequently developed intrahepatic
cholangiopathy, and venous obstruction and chronic ductopenic
rejection (n = 1). The reasons for the third transplants were
primary non-function (n = 1) and venous occlusive problems and
intrahepatic biliary stricturing (n = 1). There was no significant
difference in the occurrence of infectious complications between
the steroids and no-steroids groups, including in wound infec-
tions (30% and 18%, respectively; P = 0.16).
Metabolic outcomes in the two groups were compared
(Table 3). Baseline patient characteristics demonstrated that cho-
lesterol levels (157 14 versus 125 6; P = 0.04) and low-density
lipoprotein (LDL) levels (94 13 mg/dl versus 65 4 mg/dl; P =
0.04) were higher in the no-steroids group than in the steroids
group. The two groups were otherwise well matched with respect
to BMI, high-density lipoprotein (HDL), triglycerides, creatinine,
frequency of hypertension, number of anti-hypertensive medica-
tions, diabetes mellitus, and administration of insulin. At 6
months and 1 year following transplantation, the baseline differ-
ences in cholesterol and LDL levels disappeared. At 6 months
Table 1 Comparison of donor and recipient characteristics in groups
of liver transplant recipients randomized to either standard immu-
nosuppression (steroids) or complete avoidance of steroids (no
steroids)
Steroids
group
(n = 50)
No-steroids
group
(n = 50)
P-value
Recipient characteristics
Age, years, mean  SD 54  1 56  1 0.23
Male, % 76 76 1.00
White, % 92 86 0.34
Basiliximab inductiona, % 24 26 0.82
Primary diagnosisb, %
Hepatitis C virus 62 46 0.11
Alcohol-related 38 46 0.42
Hepatocellular carcinoma 18 22 0.62
PBC/PSC 2 10 0.09
Cryptogenic cirrhosis 16 14 0.78
Body mass index, kg/m2,
mean  SD
29  1 30  1 0.42
On preoperative
anti-hypertensive, %
74 72 0.82
Preoperative diabetes mellitus,
%
24 40 0.09
Preoperative CAD, % 6 10 0.46
Preoperative haemodialysis, % 2 6 0.31
Laboratory MELD score,
mean  SD
16  1 18  1 0.17
Liver warm ischaemic time,
min, mean  SD
64  7 54  3 0.19
Liver cold ischaemic time, min,
mean  SD
518  34 518  24 0.99
Donor characteristics
Age, years, mean  SD 38  3 37  2 0.90
Male, % 62 75 0.18
White, % 78 82 0.62
Death from stroke, % 51 51 1.00
Cytomegalovirus-positive, % 70 64 0.54
aAdministered only to patients with acute renal failure or oliguria at the
time of transplantation.
bSome recipients had more than one diagnosis.
SD, standard deviation; PBC, primary biliary cirrhosis; PSC, primary
sclerosing cholangitis; CAD, coronary artery disease; MELD, Model for
End-stage Liver Disease.
Table 2 Comparison of complications occurring in the first year
post-transplant in liver transplant recipients randomized to either
standard immunosuppression (steroids) or complete avoidance of
steroids (no steroids)
Steroids
group
(n = 50)
No-steroids
group
(n = 50)
P-value
Acute cellular rejection, % 14 20 0.42
Time to first episode,
days, mean  SD
68  20 56  32 0.76
Ductopenic rejection, % 8 2 0.17
HCV recurrence, % 48 30 0.07
Primary non-function, % 4 6 0.65
Hepatic artery thrombosis, % 4 4 1.00
Hepatic vein/IVC stenosis, % 6 16 0.11
Biliary complications, % 46 48 0.84
Postoperative acute renal
failure, %
24 36 0.19
Postoperative chronic renal
failure, %
10 22 0.10
Duration of HD, days,
mean  SD
273  165 302  109 0.88
Reoperation for bleeding, % 16 16 1.00
Retransplantation, % 0 12 0.01
Infectious complications
Surgical site infection, % 30 18 0.16
Pneumonia (%) 4 14 0.08
Urinary tract infection, % 8 14 0.34
Bloodstream infection, % 2 6 0.31
Peritonitis, % 4 8 0.40
Any infection, % 44 52 0.42
SD, standard deviation; HCV, hepatitis C Virus; IVC, inferior vena cava;
HD, hospital days.
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following liver transplantation, the only significant difference
between the two groups referred to the increased serum creatinine
level in the no-steroids group (1.60  0.14 mg/dl versus 1.24 
0.11 mg/dl; P = 0.05). Although both groups required fewer anti-
hypertensive medications at 1 year following transplantation, the
no-steroids group required significantly less (0.50  0.10 versus
0.86  0.15; P = 0.05).
Thirty-one of 50 patients (62%) in the steroids group and 23 of
50 patients (46%) in the no-steroids group had HCV infection.
Incidences of recurrent HCVwere similar between the no-steroids
and standard therapy groups (30% versus 48%, respectively; P =
0.07). However, increased graft fibrosis was noted in recipients in
the no-steroids group compared with the steroids group (Ishak
scores: 2.6  0.5 versus 1.5  0.2, respectively; P = 0.05).
Although the difference between the groups in graft survival
was not statistically different, Kaplan–Meier survival analysis
demonstrated a possible decrease in graft survival in the
no-steroids group. Rates of graft survival in the no-steroids and
steroids groups, respectively, at 1, 3 and 5 years following trans-
plantation were 76% versus 76%, 64% versus 74%, and 56%
versus 72%, respectively (P = 0.09 with a 9-year follow-up)
(Fig. 2). Overall patient survival also showed an insignificant
trend towards decreased survival in the no-steroids group. Rates
of recipient survival in the no-steroids and steroids groups,
respectively, at 1, 3 and 5 years following transplantation were
80% versus 86%, 68% versus 76% and 60% versus 72%, respec-
tively (P = 0.11 with a 9-year follow-up) (Fig. 3).
Discussion
Steroids remain a mainstay of treatment following liver transplan-
tation but their administration is associated with considerable
morbidity. In the present study, the potential benefit of complete
steroids avoidance was prospectively investigated. Although
recipient and graft survival rates at 1, 3 and 5 years did not differ
significantly, there was a concerning trend towards decreased
Table 3 Comparison of metabolic outcomes in liver transplant recipi-
ents randomized to either standard immunosuppression (steroids) or
complete avoidance of steroids (no steroids)
Steroids
group
(n = 50)
No-steroids
group
(n = 50)
P-value
Body mass index, kg/m2, mean  SD
Pre-transplant 29  1 30  1 0.42
6 months post-transplant 27  1 26  1 0.57
1 year post-transplant 28  1 29  1 0.67
Cholesterol, mg/dl, mean  SD
Pre-transplant 125  6 157  14 0.04
6 months post-transplant 154  8 172  16 0.33
1 year post-transplant 167  11 148  8 0.18
High-density lipoprotein, mg/dl, mean  SD
Pre-transplant 44  3 44  4 0.95
6 months post-transplant 42  3 40  3 0.69
1 year post-transplant 45  3 45  3 0.99
Low-density lipoprotein, mg/dl, mean  SD
Pre-transplant 65  4 94  13 0.04
6 months post-transplant 81  7 101  15 0.24
1 year post-transplant 88  11 76  6 0.37
Triglycerides, mg/dl, mean  SD
Pre-transplant 81  8 97  7 0.14
6 months post-transplant 147  12 148  17 0.96
1 year post-transplant 174  16 142  11 0.10
Creatinine, mg/dl, mean  SD
Pre-transplant 1.26  0.13 1.31  0.14 0.79
6 months post-transplant 1.24  0.11 1.60  0.14 0.05
1 year post-transplant 1.42  0.16 1.67  0.15 0.24
Anti-hypertensive medications, mean  SD
Pre-transplant 1.76  0.16 1.70  0.17 0.91
6 months post-transplant 0.61  0.13 0.72  0.14 0.58
1 year post-transplant 0.86  0.15 0.50  0.10 0.05
Insulin-dependent, %
Pre-transplant 18 22 0.62
6 months post-transplant 22 27 0.58
1 year post-transplant 23 27 0.71
Pre-transplant diabetes
mellitus, %
24 40 0.09
Post-transplant diabetes
mellitus, %
37 43 0.54
On pre-transplant
anti-hypertensive, %
74 72 0.82
On post-transplant
anti-hypertensive, %
47 55 0.42
SD, standard deviation.
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Figure 2 Graft survival in liver transplant recipients randomized to
either standard immunosuppression (steroids) or complete avoid-
ance of steroids (no steroids). P = 0.09 with 9-year follow-up
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patient and graft survival in the steroids-free arm of the trial
compared with the group receiving standard immunosuppres-
sion. Although there were no differences between the groups in
incidences of acute rejection, chronic rejection and recurrent
HCV, need for retransplant, extent of graft fibrosis and mean
6-month post-transplant serum creatinine were significantly
worse in the no-steroids group. Contrary to this study hypothesis,
recipients receiving steroids required more anti-hypertensive
medication at 1 year post-transplant. Overall, complete steroids
avoidance seemed to have minimal clinical benefit, but findings
indicate that it may lead to potentially higher morbidity and
mortality.
To minimize the longterm consequences of chronic steroid use,
steroid withdrawal within the first year of liver transplantation has
become standard.8,9 Several studies, using many different immu-
nosuppression regimens, have investigated either complete ster-
oids avoidance22,25,29 or the induction of immunosuppression
without steroids after the administration of perioperative ster-
oids.8,9,19,20 Some of these studies have also substituted steroids for
a different immunosuppressant medication. A single-arm pro-
spective study in which subjects were given a single intraoperative
dose of steroids followed by daclizumab, MMF and tacrolimus
demonstrated this to be a safe regimen and achieved patient sur-
vival of 96% at 6 months.19 A small trial in which all patients
received two perioperative doses of steroids and were then rand-
omized to tacrolimus and steroids or tacrolimus and MMF
without steroids found no difference in safety and effectiveness
between the two protocols.20 Pirenne et al. compared a group of 21
liver transplant recipients who received no steroids with a histori-
cal group of controls and found no difference in rejection or
3-year patient and graft survival.25 One study replaced steroid
induction and maintenance with rabbit antithymocyte globulin
and found no difference in graft and patient survival or rates of
rejection at 1 year.22 Meta-analyses and meta-regression of 19
randomized trials resulted in inconclusive data as a result of the
extreme heterogeneity of the trials themselves.29 Follow-up meta-
analyses of liver transplant recipients for any indication in 21
RCTs showed no differences between steroids-free protocols and
protocols including steroids for most of the parameters analysed.30
Furthermore, steroids avoidance protocols were recently exam-
ined in nine non-renal transplant studies. Seven of these studies
investigated the impact of steroid withdrawal on liver recipients
and found no difference in rates of acute rejection or patient and
graft survival.31 To date, no significant difference in patient or
graft survival has been noted in any study examining steroids
avoidance, including the present RCT.
Prior studies investigating the mitigation of the potential side-
effects of steroids have resulted in mixed findings. Steroids have
been associated with increased incidences of hypertension,32 post-
transplant diabetes18,27,32 and steroid-resistant rejection,18 and
higher cholesterol levels.27 The advantages of steroids avoidance
demonstrated in the present study included a decreased require-
ment for anti-hypertensive medication at 1 year post-transplant
and the maintenance of relatively stable cholesterol levels during
the post-transplant period. However, there was no difference in
insulin use between the steroids and no-steroids groups. Of
concern, liver recipients in the steroids-free arm of the trial had
elevated serum creatinine at 6 months after transplant compared
with the standard immunosuppression group. Although prior
studies did not demonstrate a difference in either post-transplant
patient or graft survival,18,27,32 the results of the present study are
concerning because they indicate a potentially unacceptable
decrease in patient and graft survival associated with complete
steroids avoidance.
The incidence of rejection in the present study was similar in
both groups and none of the patients were steroid-resistant. Two
thirds of the patients in the no-steroids group were never given
steroids for either the induction or maintenance of immunosup-
pression. A prospective trial in which patients were randomized to
receive tacrolimus and either dacluzimab or steroids after an
intraoperative dose of steroids showed no difference in the inci-
dence of rejection, but a lower incidence of steroid-resistant rejec-
tion in recipients who had not been given postoperative steroids.18
In a small single-centre trial, a 6-year follow-up of steroids-free
management with tacrolimus and dacluzimab induction showed
no difference in patient or graft survival between the groups
receiving induction treatment with tacrolimus or steroids, respec-
tively.33 A randomized study of 45 patients who underwent pro-
tocol biopsies showed no significant difference in 2-year rejection
rates.27 Other studies in which protocol biopsies were performed
at 1 week showed high rejection rates of 70% in steroids-free
patients.6,26 It is unclear whether these biopsy findings are clini-
cally significant.
Steroids play a role in the recurrence of HCV following liver
transplantation. The present study defined HCV recurrence as a
persistent elevation of liver enzymes to 1.5 times the normal
Figure 3 Patient survival in liver transplant recipients randomized to
either standard immunosuppression (steroids) or complete avoid-
ance of steroids (no steroids). P = 0.11 with 9-year follow-up
HPB 291
HPB 2013, 15, 286–293 © 2012 International Hepato-Pancreato-Biliary Association
level for 3 months consecutively that could not be explained by
any other diagnosis,28 and found a non-significant increased trend
towards recurrent disease in the steroids group. When transplant
liver biopsies were performed, liver recipients in the no-steroids
group demonstrated a higher Ishak score for graft fibrosis despite
their decreased rate of HCV recurrence. By contrast, a prospective
randomized trial of steroids avoidance in HCV-positive patients
showed higher rates of HCV recurrence with steroids.23 In addi-
tion, a recent randomized,multicentre European study showed no
difference in HCV viral load between groups using and not using
steroids avoidance protocols and higher recurrence rates in the
steroids arm. However, the results of this study were inconclusive
because protocol completion rates were poor.34 The dynamics of
HCV RNA replication have been found to be faster in liver allo-
graft recipients receiving steroids than in those who are not.27 By
contrast with the present study, other studies have described more
severe HCV recurrence in recipients on steroids. For example, a
prospective trial in which all patients received an intraoperative
dose of steroids and were then randomized to receive tacrolimus
alone or tacrolimus with steroids found less severe recurrent HCV
in patients who did not receive postoperative steroids.21 Further-
more, a small study of hepatitis C patients randomized to steroids
or no steroids showed a trend towards advanced fibrosis at 1 year
in the steroids-free group.24 The influence of maintenance steroids
on HCV recurrence remains unclear.
This single-centre, prospective randomized trial has the advan-
tage of longterm follow-up and suggests evidence that contrasts
with the findings of many recent clinical trials investigating ster-
oids avoidance. The principal strength of this study, compared
with other similar trials, refers to the complete absence of any use
of steroids in the steroids-free arm. Many steroids avoidance pro-
tocols reviewed here include the administration of single doses or
short tapers of steroids in the intraoperative or immediate post-
operative periods. However, this study is limited by its small
sample size and the fact that 32% of patients in the steroids-free
arm received steroids for various clinic reasons. Additionally, pro-
tocol biopsies were not employed in this study. Finally, although
the differences that emerged between the groups in this study did
not reach statistical significance, they do demonstrate a concern-
ing trend. Statistical significance may not have been achieved as a
result of the low power of the study and type II error. Given that
the null hypothesis shows no difference between the arms of the
study but may be false, the statistics presented here may actually
accept the null in error, given the power of the study.
Complete avoidance of steroids appears to provide liver trans-
plant recipients with minimal benefit. Furthermore, complete
steroids avoidance during liver transplantation was associated
with worse post-transplant renal function, a concerning trend
towards increased graft loss, accelerated allograft fibrosis related
to recurrent HCV, need for retransplantation and a possible
increase in recipient mortality rates. The extreme heterogeneity of
studies conducted to date makes any conclusive finding difficult to
interpret. However, the findings presented in the present study
suggest that following liver transplantation, at least a short course
of induction or maintenance steroids should be used.
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